It is the French pharmaceutical company Ipsen Pharma’s drug Ojemda (tovorafenib) that has now received the green light for the treatment of pediatric low-grade glioma in children from six months of age.
The disease is the most common brain tumour in children, and although it is benign and survival rates are high, it can lead to long-term complications for affected children. The tumor may grow into sensitive and vital structures, resulting in impaired vision, movement, learning ability, and overall development. The consequences can include a significantly reduced quality of life. The decision to recommend a conditional approval was made at the EMA’s scientific committee meeting last Friday.
BREAKING